JP2022504036A5 - - Google Patents
Info
- Publication number
- JP2022504036A5 JP2022504036A5 JP2021517954A JP2021517954A JP2022504036A5 JP 2022504036 A5 JP2022504036 A5 JP 2022504036A5 JP 2021517954 A JP2021517954 A JP 2021517954A JP 2021517954 A JP2021517954 A JP 2021517954A JP 2022504036 A5 JP2022504036 A5 JP 2022504036A5
- Authority
- JP
- Japan
- Prior art keywords
- reuptake inhibitors
- agent
- antidepressant
- serotonin
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024078458A JP2024105527A (ja) | 2018-10-05 | 2024-05-14 | 大うつ病性障害を治療するためのエスケタミンの投与計画 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862741562P | 2018-10-05 | 2018-10-05 | |
| US62/741,562 | 2018-10-05 | ||
| PCT/IB2018/059107 WO2020070547A1 (en) | 2018-10-05 | 2018-11-19 | Dosage regime of esketamine for treating major depressive disorder |
| IBPCT/IB2018/059107 | 2018-11-19 | ||
| US201962867354P | 2019-06-27 | 2019-06-27 | |
| US62/867,354 | 2019-06-27 | ||
| PCT/IB2019/058476 WO2020070706A1 (en) | 2018-10-05 | 2019-10-04 | Dosage regime of esketamine for treating major depressive disorder |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024078458A Division JP2024105527A (ja) | 2018-10-05 | 2024-05-14 | 大うつ病性障害を治療するためのエスケタミンの投与計画 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022504036A JP2022504036A (ja) | 2022-01-13 |
| JP2022504036A5 true JP2022504036A5 (cg-RX-API-DMAC7.html) | 2023-11-10 |
Family
ID=70551470
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021517954A Pending JP2022504036A (ja) | 2018-10-05 | 2019-10-04 | 大うつ病性障害を治療するためのエスケタミンの投与計画 |
| JP2024078458A Pending JP2024105527A (ja) | 2018-10-05 | 2024-05-14 | 大うつ病性障害を治療するためのエスケタミンの投与計画 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024078458A Pending JP2024105527A (ja) | 2018-10-05 | 2024-05-14 | 大うつ病性障害を治療するためのエスケタミンの投与計画 |
Country Status (9)
| Country | Link |
|---|---|
| US (9) | US11865088B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3860579A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2022504036A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210074275A (cg-RX-API-DMAC7.html) |
| CN (1) | CN112702995A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019352028A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3113198A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL280845A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020070706A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3043785T3 (da) | 2013-09-13 | 2021-11-15 | Univ Chiba Nat Univ Corp | Anvendelse af r-ketamin og salt deraf som lægemidler |
| WO2019160057A1 (ja) | 2018-02-15 | 2019-08-22 | 国立大学法人千葉大学 | 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物 |
| CN118121577A (zh) | 2018-05-04 | 2024-06-04 | 感知神经科学公司 | 治疗物质滥用的方法 |
| CA3103440A1 (en) | 2018-06-27 | 2020-01-02 | Clexio Biosciences Ltd. | Method of treating major depressive disorder |
| WO2020070706A1 (en) | 2018-10-05 | 2020-04-09 | Clexio Biosciences Ltd. | Dosage regime of esketamine for treating major depressive disorder |
| US11324707B2 (en) | 2019-05-07 | 2022-05-10 | Clexio Biosciences Ltd. | Abuse-deterrent dosage forms containing esketamine |
| US12589083B2 (en) | 2019-05-07 | 2026-03-31 | Clexio Biosciences Ltd. | Abuse-deterrent dosage forms containing esketamine |
| WO2021137147A1 (en) | 2019-12-30 | 2021-07-08 | Clexio Biosciences Ltd. | Dosage regime with esketamine for treating major depressive disorder |
| JP2023507926A (ja) | 2019-12-30 | 2023-02-28 | クレキシオ バイオサイエンシーズ エルティーディー. | 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画 |
| EP3949956A1 (en) * | 2020-08-06 | 2022-02-09 | LTS Lohmann Therapie-Systeme AG | Esketamine-suspension-tts |
| US20240197652A1 (en) | 2021-05-25 | 2024-06-20 | Awakn Ls Europe Holdings Limited | Ketamine in the treatment of behavioral addictions |
| US12396981B2 (en) | 2023-03-09 | 2025-08-26 | William Shulman | Methods of using DMT |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH535201A (de) | 1969-12-19 | 1973-03-31 | Bristol Myers Co | Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren |
| WO2004004693A1 (en) | 2002-07-05 | 2004-01-15 | Collgegium Pharmaceutical | Abuse-deterrent pharmaceutical compositions of opiods and other drugs |
| JP2009530385A (ja) * | 2006-03-22 | 2009-08-27 | マウント シナイ スクール オブ メディシン | うつ病の治療のためのケタミンの鼻内投与 |
| US20080069891A1 (en) | 2006-09-15 | 2008-03-20 | Cima Labs, Inc. | Abuse resistant drug formulation |
| SA07280459B1 (ar) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني |
| DE102007009888A1 (de) * | 2007-02-28 | 2008-09-04 | Hermann, Holger Lars, Dr. | Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen |
| CN105534936B (zh) | 2007-08-13 | 2020-07-31 | Ohemo 生命科学股份有限公司 | 抗滥用药物、使用方法和制备方法 |
| WO2009137843A2 (en) | 2008-05-09 | 2009-11-12 | Emory University | Nmda receptor antagonists for the treatment of neuropsychiatric disorders |
| US20120225949A1 (en) | 2009-08-14 | 2012-09-06 | Demitri Papalos | Compositions and methods for treating bipolar disorder |
| US20110038807A1 (en) | 2009-08-14 | 2011-02-17 | Demitri Papolos | Compositions and methods for treating bipolar disorder |
| US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| WO2013138322A1 (en) | 2012-03-12 | 2013-09-19 | Janssen Pharmaceutica Nv | Esketamine for the treatment of treatment-refractory or treatment-resistant depression |
| JP2015521988A (ja) | 2012-07-06 | 2015-08-03 | イガレット・リミテッド | 制御放出用乱用防止性医薬組成物 |
| US20140079740A1 (en) | 2012-08-02 | 2014-03-20 | ClinPharm Support GmbH | Oral transmucosal adminstration forms of s-ketamine |
| US9468611B2 (en) | 2012-09-27 | 2016-10-18 | Relmada Therapeutics, Inc. | d-Methadone for the treatment of psychiatric symptoms |
| US10555916B2 (en) | 2013-01-25 | 2020-02-11 | Case Western Reserve University | NMDAR antagonist for the treatment of pervasive development disorders |
| KR20220044380A (ko) | 2013-04-12 | 2022-04-07 | 이칸 스쿨 오브 메디슨 엣 마운트 시나이 | 외상후 스트레스 장애의 치료 방법 |
| US9913803B2 (en) | 2013-08-26 | 2018-03-13 | Amorsa Therapeutics, Inc. | Single-layer oral dose of neuro-attenuating ketamine |
| WO2015051259A1 (en) | 2013-10-04 | 2015-04-09 | Impax Laboratories, Inc. | Pharmaceutical compositions and methods of use |
| WO2015066172A1 (en) | 2013-10-31 | 2015-05-07 | Cima Labs Inc. | Immediate release abuse-deterrent granulated dosage forms |
| EP3272338B1 (en) | 2014-04-17 | 2020-09-09 | Develco Pharma Schweiz AG | Oral dosage form of ketamine |
| EP3193853A1 (en) | 2014-09-15 | 2017-07-26 | Janssen Pharmaceutica NV | VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION |
| KR102604397B1 (ko) | 2014-11-04 | 2023-11-21 | 아카디아 파마슈티칼스 인코포레이티드 | 신경 감쇠 케타민 및 노르케타민 화합물, 이의 유도체, 및 방법 |
| CA2970065A1 (en) | 2014-12-08 | 2016-06-16 | Cima Labs Inc. | Immediate release abuse-deterrent granulated dosage forms |
| US20160332962A1 (en) | 2015-05-13 | 2016-11-17 | Janssen Pharmaceutica Nv | (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine |
| US20160338977A1 (en) * | 2015-05-20 | 2016-11-24 | Janssen Pharmaceutica Nv | Methods and kits for treating depression |
| WO2017041112A1 (en) * | 2015-09-04 | 2017-03-09 | Cyprus Therapeutics, Inc. | Ketamine and cytochrome p 450 inhibitor combinations |
| EP3377050A4 (en) | 2015-11-17 | 2019-11-20 | The Trustees of Columbia University in the City of New York | PHARMACOLOGICAL PROPHYLACTICS AGAINST STRESS-INDUCED AFFECTIVE DISORDERS AND THEIR ASSOCIATED SYMPTOMS |
| WO2018079693A1 (ja) | 2016-10-27 | 2018-05-03 | 国立大学法人 千葉大学 | (s)-ノルケタミンおよびその塩の医薬品としての応用 |
| WO2018102488A1 (en) | 2016-11-30 | 2018-06-07 | Wolfson Philip E | Ketamine for the treatment of menstrually related symptoms |
| EP3641742B1 (en) | 2017-06-23 | 2026-03-25 | Ketabon GmbH | Hydroxynorketamine for the use in the treatment of depression |
| MX2020003546A (es) | 2017-10-10 | 2020-08-03 | Douglas Pharmaceuticals Ltd | Formulacion farmaceutica de liberacion prolongada y metodos de tratamiento. |
| SG11202005896WA (en) | 2017-12-22 | 2020-07-29 | Janssen Pharmaceuticals Inc | Esketamine for the treatment of depression |
| CA3103440A1 (en) | 2018-06-27 | 2020-01-02 | Clexio Biosciences Ltd. | Method of treating major depressive disorder |
| WO2020070706A1 (en) | 2018-10-05 | 2020-04-09 | Clexio Biosciences Ltd. | Dosage regime of esketamine for treating major depressive disorder |
| WO2020075134A1 (en) | 2018-10-11 | 2020-04-16 | Clexio Biosciences Ltd. | Esketamine for use in treating major depressive disorder |
| US11324707B2 (en) | 2019-05-07 | 2022-05-10 | Clexio Biosciences Ltd. | Abuse-deterrent dosage forms containing esketamine |
| EP3923920A4 (en) | 2019-08-05 | 2022-11-23 | The Ketamine Research Foundation | KETAMINE FOR THE TREATMENT OF SYMPTOMS AND DISORDERS AFTER CHILDREN |
| TW202135787A (zh) | 2019-12-12 | 2021-10-01 | 比利時商健生藥品公司 | 艾氯胺酮調配物及製備與儲存的方法 |
| WO2021137147A1 (en) | 2019-12-30 | 2021-07-08 | Clexio Biosciences Ltd. | Dosage regime with esketamine for treating major depressive disorder |
-
2019
- 2019-10-04 WO PCT/IB2019/058476 patent/WO2020070706A1/en not_active Ceased
- 2019-10-04 AU AU2019352028A patent/AU2019352028A1/en not_active Abandoned
- 2019-10-04 CN CN201980058745.4A patent/CN112702995A/zh active Pending
- 2019-10-04 KR KR1020217006938A patent/KR20210074275A/ko not_active Ceased
- 2019-10-04 US US16/592,930 patent/US11865088B2/en active Active
- 2019-10-04 EP EP19782762.9A patent/EP3860579A1/en not_active Withdrawn
- 2019-10-04 CA CA3113198A patent/CA3113198A1/en active Pending
- 2019-10-04 JP JP2021517954A patent/JP2022504036A/ja active Pending
-
2021
- 2021-02-14 IL IL280845A patent/IL280845A/en unknown
- 2021-04-13 US US17/229,623 patent/US11253487B2/en active Active
-
2022
- 2022-01-10 US US17/571,731 patent/US12016832B2/en active Active
-
2023
- 2023-03-30 US US18/193,122 patent/US11957645B2/en active Active
- 2023-11-08 US US18/504,388 patent/US12280022B2/en active Active
- 2023-11-14 US US18/508,826 patent/US12514831B2/en active Active
- 2023-11-22 US US18/517,062 patent/US12336970B2/en active Active
-
2024
- 2024-05-14 JP JP2024078458A patent/JP2024105527A/ja active Pending
-
2025
- 2025-03-06 US US19/072,349 patent/US20250195454A1/en active Pending
- 2025-05-21 US US19/214,604 patent/US20250281428A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11786491B2 (en) | Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders | |
| JP2015516395A5 (cg-RX-API-DMAC7.html) | ||
| JP2011523949A5 (cg-RX-API-DMAC7.html) | ||
| JP2023100904A5 (cg-RX-API-DMAC7.html) | ||
| JP5827239B2 (ja) | フマギロール型化合物並びにその製造方法及び使用方法 | |
| RU2016143091A (ru) | Органические соединения | |
| JP6479670B2 (ja) | 7,8−ジヒドロキシフラボンおよび7,8−置換フラボン誘導体、組成物、およびそれらに関連する方法 | |
| HRP20110206T1 (hr) | Derivati 3-(heteroaril-oksi)-2-alkil-1-aza-bicikloalkila kao alfa.7-nachr liganda za liječenje cns bolesti | |
| JP2017509686A5 (cg-RX-API-DMAC7.html) | ||
| RU2020123764A (ru) | Органические соединения | |
| RU2018137496A (ru) | Органические соединения | |
| JP2021511365A5 (cg-RX-API-DMAC7.html) | ||
| JP2002516282A (ja) | 難治性鬱病の処置のための組合せ治療 | |
| MXPA06002619A (es) | Procedimiento para el tratamiento de trastornos de depresion y ansiedad mediante terapia de combinacion. | |
| EP2509589B1 (fr) | Compositions antivirales pharmaceutiques ou vétérinaires comprenant la midodrine ou la desglymidodrine | |
| JP2023507926A5 (cg-RX-API-DMAC7.html) | ||
| JP2022506113A5 (cg-RX-API-DMAC7.html) | ||
| JP2007513052A5 (cg-RX-API-DMAC7.html) | ||
| JP2013032308A5 (cg-RX-API-DMAC7.html) | ||
| JP2016520112A5 (cg-RX-API-DMAC7.html) | ||
| TWI455712B (zh) | 增強神經藥方療效的山梨酸與苯甲酸及其衍生物 | |
| JP2009542820A5 (cg-RX-API-DMAC7.html) | ||
| WO2012083034A1 (en) | Modulation of neurotrophic factors by omega-3 fatty acid formulations | |
| JP2024541315A5 (cg-RX-API-DMAC7.html) | ||
| JP2024538015A5 (cg-RX-API-DMAC7.html) |